Sanofi's Sarclisa (isatuximab) has gained approval from Japan’s Ministry of Health, Labour and Welfare for use in conjunction ...

Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed MM patients Approval based on positive results from ...

The Japanese Ministry of Health, Labor and Welfare (MHLW) in Japan has approved Sarclisa (isatuximab), in combination with ...

The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly ...

Japanese MHLW approves Sarclisa for patients with newly diagnosed multiple myeloma: Paris Wednesday, February 26, 2025, 09:00 Hrs [IST] The Ministry of Health, Labour and Welfare ...

Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed MM patients Approval based on positive results from ...

Sanofi is trumpeting new data for its anti-CD38 drug Sarclisa as it tries to capture market share from Johnson & Johnson’s blockbuster Darzalex in the multiple myeloma market. A couple of months ...

Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma after the US regulator gave it a priority review. The French pharma ...

Gene therapy stocks are transforming healthcare with revolutionary treatments. Therefore, as this sector continues to evolve, ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

The study showed that Sarclisa's addition to VRd significantly improved progression-free survival compared with VRd alone in patients with newly diagnosed, transplant-ineligible multiple myeloma.

The expansion of the advanced therapy medicinal products market is primarily fueled by the increasing incidence of chronic diseases. The rising prevalence of genetic disorders and cancer, along ...